PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Merck
Merck Gets to the Heart of the Matter
Merck may have succeeded in making a molecule that increases “good cholesterol,” which is likely the only real breakthrough left in the anti-cholesterol and hypertension market.
It has long been known that elevated LDL cholesterol and reduced HDL cholesterol are major risk factors for developing cardiovascular disease. And while much ado has been made about a [...]
Merck to Close Eight Plants
Image by Getty Images via @daylife
Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.”
Taking a page out of Pfizer’s book [...]
Posted in Strategy Also tagged business, Canada, Factory, Infectious disease, Research and development, Schering Plough, South America 3 Comments
Abbott Shells Out $3.7 Billion for Piramal
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy Also tagged Abbott, branded generics, Diabetes, Eli Lilly, Emerging Markets, generics, india, Oncology, Piramal Leave a comment
Cold Cuts: Merck Layoffs Loom
Image via Wikipedia
It is not just cold outside these days, as Merck & Co. makes some cold hard decisions. Following on the heels of its now closed acquisition of Schering-Plough, Merck is making significant job cuts across its operations. Some 16,000 jobs are expected to be eliminated in total as a result of the merger.
According [...]
Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday